ARVN: LRRK2 and PSP lead a focused pipeline, with major data and partnership milestones expected by 2026
Less than 1 min read
A strategic reset has prioritized five early-stage assets, with LRRK2 and PSP leading the pipeline and key data readouts expected in 2026. Vepdegestrant is being actively partnered, and the company maintains a strong cash position into 2028. Oncology programs, including BCL6, are also advancing.
Based on Arvinas, Inc. [ARVN] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 18 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr